Meeting
2019 ASCO Annual Meeting
Phase I/II study of depatuxizumab mafodotin (ABT-414) monotherapy or combination with temozolomide in Japanese patients with/without EGFR-amplified recurrent glioblastoma.
Authors
Yoshitaka Narita
National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
Yoshitaka Narita , Yoshihiro Muragaki , Takashi Maruyama , Naoki Kagawa , Katsunori Asai , Junichiro Kuroda , Kazuhiko Kurozumi , Motoo Nagane , Masahid Matsuda , Keisuke Ueki , Christopher Joseph Ocampo , Ikiru Matsumoto , Reiko Odagawa , Yasuko Nishimura , Kazuhiko Mishima
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Brain Metastases
Clinical Trial Registration Number
NCT02590263
Citation
J Clin Oncol 37, 2019 (suppl; abstr 2065)
DOI
10.1200/JCO.2019.37.15_suppl.2065
Abstract #
2065
Poster Bd #
254
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Depatuxizumab mafodotin (Depatux-M) plus temozolomide (TMZ) in recurrent glioblastoma patients: Real-world experience from a multicenter study of Italian Association of Neuro-Oncology (AINO).
First Author: Mario Caccese
Poster
2018 ASCO Annual Meeting
Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux –M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406).
First Author: Martin J. Van Den Bent
Poster
2016 ASCO Annual Meeting
Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, as monotherapy in epidermal growth factor receptor (EGFR) amplified, recurrent glioblastoma (GBM).
First Author: Martin J. Van Den Bent
Poster
2016 ASCO Annual Meeting
Phase I/II study of VAL-083 in patients with recurrent glioblastoma.
First Author: Kent C. Shih